Guardant Health (GH) CFO sells shares and reports RSU vesting
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Guardant Health, Inc. Chief Financial Officer Michael Brian Bell reported a mix of equity compensation vesting and share dispositions. On March 15, 2026, restricted stock units and performance-based restricted stock units covering a total of 13,790 shares of Common Stock vested and were converted at a $0.0000 exercise price. To satisfy tax obligations on this vesting, 7,413 shares were withheld by the company at a price of $85.4900 per share. On March 16, 2026, Bell completed an open-market sale of 3,000 shares of Common Stock at a weighted average price of $87.0370 per share. After these transactions, he directly holds 43,601 shares of Guardant Health Common Stock.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Seller: 3,000 shares ($261,111)
Net Sell
8 txns
Insider
Bell Michael Brian
Role
Chief Financial Officer
Sold
3,000 shs ($261K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 3,000 | $87.037 | $261K |
| Exercise | Restricted Stock Units | 1,233 | $0.00 | -- |
| Exercise | Performance-Based Restricted Stock Units | 10,518 | $0.00 | -- |
| Exercise | Restricted Stock Units | 2,039 | $0.00 | -- |
| Exercise | Common Stock | 1,233 | $0.00 | -- |
| Exercise | Common Stock | 10,518 | $0.00 | -- |
| Exercise | Common Stock | 2,039 | $0.00 | -- |
| Tax Withholding | Common Stock | 7,413 | $85.49 | $634K |
Holdings After Transaction:
Common Stock — 43,601 shares (Direct);
Restricted Stock Units — 0 shares (Direct);
Performance-Based Restricted Stock Units — 0 shares (Direct)
Footnotes (1)
- These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $87.0001 to $87.1500. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. This represents a restricted stock unit award granted on May 9, 2022 that vested over a four-year period. 25% of the shares subject to such award vested on March 15, 2023 and the remaining 75% of the shares vested in equal quarterly installments over the remaining three-year period thereafter. Not applicable for Restricted Stock Units. This represents a performance-based restricted stock unit award granted on June 7, 2023 with a 3-year performance metric. The second tranche metric was achieved and the shares vested on March 15, 2026. This represents a restricted stock unit award granted on June 9, 2023 that vests over a three-year period. 33% of the shares subject to such award vested on June 15, 2024 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter.
FAQ
What insider transactions did Guardant Health (GH) CFO Michael Brian Bell report?
Michael Brian Bell reported vesting of restricted and performance-based stock units converting into 13,790 Guardant Health common shares, tax withholding using 7,413 shares, and an open-market sale of 3,000 shares. These actions reflect routine equity compensation events combined with a modest share disposition.
What RSU and performance-based RSU awards vested for Guardant Health (GH) CFO?
The filing shows 1,233 restricted stock units and 10,518 performance-based restricted stock units converting into Guardant Health Common Stock on March 15, 2026. These awards stem from grants made in 2022 and 2023, with vesting tied to multi-year service and performance conditions detailed in the footnotes.